Seminar | Protas - Smarter Trials for Better Health
![](/research/files/research/styles/fullwidth_breakpoints_theme_moriarty_small_1x/public/channels/image/seminar_sep_19_social_media_post-1_1.png?itok=N_zU0F41×tamp=1724339275)
Join D2R and the for this hybrid seminar with Professor Richard Haynes from Oxford University where he will present how is changing the face of clinical trials.
Randomized trials remain the best methodology to assess the efficacy and safety of treatments, BUT they are facing a crisis. Rising regulatory burden and costs mean that some effective treatments are either not developed or are only developed for a narrow indication, preventing their full benefits from being realized. Conversely, less effective treatments may not be identified, or worse, their hazards may go unrecognized. Protas, a not-for-profit organization, intends to combine smart trial design and delivery, effective use of data and technology and collaborative policy development to address this challenge and improve population health.
Agenda
11:00am-11:05am | Welcome By Mark Lathrop, D2R Scientific Director |
---|---|
11:05am-12:05pm | Protas, Smarter Trials for Better Health By Richard Haynes, Professor of Renal Medicine and Clinical Trials, Oxford University |
12:05pm-12:25pm | Q&A |
12:25pm-12:30pm | Closing Remarks |
About the Speaker:
Richard Haynes did his pre-clinical medical studies in Cambridge before moving to Oxford for his clinical studies and qualified in 2000. He came to Oxford University鈥檚 Clinical Trial Service Unit for a period of 鈥渙ut of programme鈥 research in 2006 to work on the HPS2-THRIVE trial with Prof Jane Armitage. He completed his training in renal medicine in 2011 and was appointed as an honorary consultant at the Oxford Kidney Unit. Alongside his clinical practice, his research focusses on large-scale streamlined trials. He has delivered trials in cardiovascular disease and was co-principal investigator of EMPA-KIDNEY which demonstrated the efficacy and safety of empagliflozin in people with CKD. He also led his trials unit delivery of the RECOVERY trial which was the largest trial of treatments for covid-19. He now combines his research at CTSU with his role as Chief Scientist at Protas.
Reserve Your Spot Now!
Be part of this transformative discussion on the future of medical trials.
RSVP by Tuesday September 17:
Want to attend in-person?聽Reserve your spot by emailing聽D2R.comms [at] mcgill.ca
Confirmation emails will be provided to registered participants a few days before the event.